Invega Hafyera is a long-acting injectable (LAI) formulation of Paliperidone. It is the first available antipsychotic LAI that provides coverage for 6 months. It is FDA-indicated to treat adults with schizophrenia.
Establishing Efficacy and Tolerability
Prior to initiating Invega Hafyera, treat the patient with either:
Dosing
Paliperidone Conversion from Oral to LAI Formulations | |||
PO Dose | LAI/Invega Sustenna Dose | LAI/Invega Trinza* | LAI/Invega Hafyera** |
<3 mg Paliperidone | 39 mg Invega Sustenna every 4 weeks | N/A | N/A |
3 mg Paliperidone | 78 mg Invega Sustenna every 4 weeks | 273 mg Invega Trinza every 12 weeks | N/A |
6 mg Paliperidone | 117 mg Invega Sustenna every 4 weeks | 410 mg Invega Trinza every 12 weeks | N/A |
9 mg Paliperidone | 156 mg Invega Sustenna every 4 weeks | 546 mg Invega Trinza every 12 weeks | 1,092 mg Invega Hafyera every 6 months |
12 mg Paliperidone | 234 mg Invega Sustenna every 4 weeks | 819 mg Invega Trinza every 12 weeks | 1,560 mg Invega Hafyera every 6 months |
*Stabilization with at least four months (4 injections) of Invega Sustenna required prior to initiation of Invega Trinza. **Stabilization with at least four months (4 injections) of Invega Sustenna or at least one three month cycle (1 injection) of Invega Trinza prior to initiation of Invega Hafyera. If administering a strong CYP3A4/P-glycoprotein inducer, considering managing the patient using Paliperidone extended-release tablet. References: 1. Stahl, S.M. (2017). The prescribers guide: Stahl’s essential psychopharmacology (6th ed.). New York: Cambridge University Press. 2. American Psychiatric Association. (2020). The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. American Psychiatric Association Publishing. https://doi.org/10.71176/appi.books.9780890424841 3. INVEGA SUSTENNA USPI, Section 2.8: Instructions for Use; Section 17: How Supplied/Storage and Handling 4. INVEGA TRINZA USPI, Section 2.2: Schizophrenia 5. INVEGA HAFYERA USPI, Section 2.4: Instruction for Preparation and Administration |
Practical Issues (including administration)
FDA Medication Label
Information on this topic is found in the FDA medication label. Prescribing should always be informed by the FDA medication label. Medication labels can be found searching Drugs@FDA at the FDA website. Labels are available using the Drugs@FDA app for Apple or Android devices.
Labels change over time, and the current label should always be consulted. Here is the most recent label, at time of writing.
Administration/Dosing Guide
More information about administration (including a detailed video) and dosing can be found here.
REFERENCES
If you would like more information on this topic, or would like to provide any feedback, please send us a message using our consultation system. Be sure to let us know about which tip you are writing. We would love to hear from you, and the consultation system is free to use and confidential. Thank you!